Clinical Trial: ECOG-ACRIN EA6174

ECOG-ACRIN EA6174

Status: Closed

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

Eligible for screening study DCP 001

EA6174 is closed to accrual, effective July 1, 2024.